IBM Teams Up With Pfizer For Revolutionary Health Care Technology
IBM and Pfizer have collaborated for the completion of the project which deals with remote clinical trial technology.
According to the most recent news, IBM has collaborated with Pfizer to help the latter in the attainment of its project that aims for having a “sensor-enabled remote patient monitoring” put into operation by 2019. The Big Blue is likely to build a sensor-laden connected house in order to assess the viability of the project prior to its proposed use in a Phase III Parkinson’s disease trial in 2019.
If the proposed plan is transferred exactly what has been intended, the system will be able to provide unparalleled insights on Parkinson patients’ health and activities in the period between visits of clinical trial sites. The Big Pharma looks forward to using hundreds of mobile devices and off-the-shelf sensors for the data collection of the participants’ diurnal activities. Afterwards, Pfizer will integrate the data with IBM’s machine learning capabilities in an attempt to unveil the treatment’s effects, for instance, the time taken by the medications to show the traits of efficacy.
Pfizer Head of Quantitative Medicine, Peter Bergethon, told Fortune that the company intends to use the digital revolution of continuous monitoring in order to enhance the quality of care delivery of therapeutics and clinical trials. He added, “We want to define the digital signature of a person and characterize how they’re feeling and how they’re responding to the medication.”
The Big Pharma wants the system to be completed ahead of its experimental Parkinson’s disease drug entrance into Phase III – which is more than probable to happen in 2019. The pharmaceutical company has to get a lot of work done in order to meet its goal.
Pfizer has planned to manage the huge pile of tasks by collaborating with the Big Blue for the sound execution of the project. For the project, a connected house in Yorktown Heights, New York, is being set up as well to find out how the technology will perform once introduced in a practical scenario. Around 200 participants are likely to live in the house providing IBM and Pfizer with substantial data to effectively test the technology.
This approach too will give slightly hard time as the late-phase trials demands fast pace. IBM is well aware of the challenge. IBM Research director of the computational biology center, Ajay Royyuro, expressed, “The solution has to scale. It has as to be robust enough to deploy in patient’s home and simultaneously do that in hundreds or even thousands of homes.”
It will take some time to see the plans of the pharmaceutical company transferred into the reality. Through the initiative, the company has surely on its way of the blazing the trail for remote clinical trial technology. Earlier, the company set a major hallmark when it introduced the REMOTE trial in 2011, which was the first study without any involvement of trial sites. The technology’s progress was halted because of the enrollment issues but it did provide a breakthrough for technologies and concept.
Moreover, IBM stock has been trading fairly well. At the market close on Friday, the stock’s price was reported to be $149.31. The 52-week range of the stock is $117 to $176.